Relative Bioavailability of Two Survodutide (BI 456906) Formulations When Administered Subcutaneously Via Pre-filled Syringe Over 28 Weeks (an Open-label, Randomised, Multiple Dose, Parallel Group Trial)
Latest Information Update: 04 Nov 2025
At a glance
- Drugs Survodutide (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 08 Oct 2025 New trial record